Status:
COMPLETED
The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet
Lead Sponsor:
University of North Carolina, Chapel Hill
Conditions:
Pregnancy
HIV
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
In this study, we are looking at blood concentrations of Kaletra in HIV positive patients during pregnancy. The patients will come in for 4 visits lasting \~24hrs. These visits take place at 20-24 wee...
Eligibility Criteria
Inclusion
- HIV positive
- Pregnant (\<22 weeks)
- Currently taking or planning to start Kaletra
- ≥18 years of age
Exclusion
- Active opportunistic or serious bacterial infection at the time of entry
- Past or present obstetrical complications (including, but not limited to: placentia previa, eclampsia, confirmed birth defects, multiple gestation pregnancies)
- Unable to maintain medication adherence, defined as ≥ 80% of doses taken between visits
- Currently receiving or expected to receive other protease inhibitors in conjunction with Kaletra®
- HIV genotype showing accumulation of protease inhibitor mutations expected to result in virologic failure on Kaletra® OR documented virologic failure on Kaletra®-containing regimen attributable to the Kaletra® component
- Chronic hepatitis B and/or C virus infection
- Cushing's Syndrome
- Untreated hypothyroidism or hyperthyroidism
- Serum Creatinine \> 1.5 mg/dL
- Amylase 1.5 times ULN and/or abnormal lipase
- Direct or total bilirubin levels \> Grade 1
- ALT/AST \> Grade 2 (based on the NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adverse Events
- Bicarbonate \> Grade 2 (DAIDS)
- Hematology \> Grade 2 (DAIDS), except for anemia: exclude only women with Hb\< 9 g/dL and/or HCT , 27.3% (\< 8.5 mg/dL and/or HCT , 25.6% if currently on ZDV) at screening; all subjects with anemia who enroll in the study must be receiving or start hematinics, including iron and folate supplements, immediately upon enrollment and continue until anemia resolves or end of pregnancy. The hematinic supplements may be discontinued at the discretion of the investigator if they consider continuation would not be in the best interest of the subject.
- Receiving the following drugs: astemizole, terfenadine, rifampin, cisapride, ergot derivatives, simvastatin, lovastatin, St. John's wort, pimozide, midazolam, triazolam, carbamezapine, phenobarbital, phenytoin, or dexamethasone
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00766818
Start Date
January 1 2007
End Date
March 1 2010
Last Update
May 13 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina
Chapel Hill, North Carolina, United States, 27599